Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy-Reference-Cited by-同舟云学术

Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy

Published:2021-02-05 Issue:6 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Li Lei¹²³^ORCID,Wei Jia-Ru⁴,Dong Jun¹,Lin Qing-Guang¹,Tang Hong⁵,Jia Yong-Xu⁶,Tan Wanlin¹,Chen Qing-Yun¹,Zeng Ting-Ting¹,Xing Shan¹,Qin Yan-Ru⁶,Zhu Ying-Hui¹,Li Yan¹^ORCID,Guan Xin-Yuan¹²³⁶^ORCID

Affiliation:

1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

2. Department of Clinical Oncology, The University of Hong Kong, Hong Kong 00852, China.

3. Department of Clinical Oncology Center, The University of Hongkong-Shenzhen Hospital, Shenzhen 518058, China.

4. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.

5. Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.

6. Department of Clinical Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.

Abstract

Cancer-associated fibroblast assists cancer cell in building rampart to block T cell infiltration and resist anti–PD-1 drugs.

Funder

National Natural Science Foundation of China

Shenzhen Fundamental Research Program

National Science Foundation for Distinguished Young Scholars of China

the Project funded by the National Basic Research Program of China

the China National Key Sci-Tech Special Project of Infectious Diseases

National Science Foundation of Guangdong Province

Hong Kong Research Grant Council General Research Funds

Hong Kong Theme-based Research Scheme Fund

Hong Kong Research Grant Council Collaborative Research Funds

Basic and Applied Basic Research Foundation of Guangdong Province

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference56 articles.

1. Treatment of Advanced Non–Small Cell Lung Cancer in 2018

2. Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives

3. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

4. Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy

5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAFs and T cells interplay: The emergence of a new arena in cancer combat;Biomedicine & Pharmacotherapy;2024-08

2. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment;Journal of Translational Medicine;2024-07-31

3. TGFβ‐mediated inhibition of hypodermal adipocyte progenitor differentiation promotes wound‐induced skin fibrosis;Cell Proliferation;2024-07-29

4. Extracellular vesicle‐packaged lncRNA from cancer‐associated fibroblasts promotes immune evasion by downregulating HLA‐A in pancreatic cancer;Journal of Extracellular Vesicles;2024-07

5. Hepatocyte transformation is induced by laminin γ2 monomer;Cancer Science;2024-07